Skip to content
Peptide guide

Are peptides legal?

Are peptides legal? It depends on the peptide: approved peptide medicines are legal with a prescription, some can be compounded by pharmacies, and most peptides sold online as "research use only" are not approved for human use.

This article is educational, not medical advice. Talk with a qualified healthcare professional before using any medicine or peptide.

Some are and some aren’t, depending on whether a peptide is an approved medicine, allowed in compounding, or neither. “Peptide” describes a type of molecule, not a legal category.

The rules below are for the US; other countries differ.

The three kinds of peptides, legally

Kind Examples Legal to use?
FDA-approved medicines Semaglutide, tirzepatide, insulin, tesamorelin Yes, with a prescription
Compounded prescriptions Sermorelin, and others the FDA allows Yes, with a prescription, from a licensed pharmacy
“Research use only” chemicals BPC-157, TB-500, most online peptides Not approved for human use

What does “research use only” mean?

It means the product is sold for lab experiments, not for people. Sellers use the label because selling an unapproved drug for human use is illegal, and the FDA has sent warning letters to sellers who market these products for people anyway.

These products aren’t checked for purity, strength or sterility; see research peptides.

What is FDA Category 2?

Category 2 is the FDA’s list of bulk ingredients that compounding pharmacies may not use because of possible safety risks. In 2023 the FDA added about 19 peptides, including BPC-157, TB-500, ipamorelin and CJC-1295.

What changed for peptides in 2024 and 2026?

In 2024 several peptides, including ipamorelin, CJC-1295, AOD-9604, selank and thymosin alpha-1, moved off the pharmacy (503A) Category 2 list after their nominations were withdrawn. In 2026 most of the rest followed, and in July 2026 an FDA advisory committee recommended allowing six (BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax) in pharmacy compounding.

Leaving Category 2 isn’t an approval, and the FDA still has to make final decisions.

Mostly not anymore. Compounded copies were allowed only while the drugs were in shortage, which ended in December 2024 for tirzepatide and February 2025 for semaglutide.

In April 2026 the FDA also proposed removing both from the list that large compounding facilities can use.

Many are banned. The World Anti-Doping Agency prohibits growth hormone-releasing peptides like CJC-1295, ipamorelin and tesamorelin, plus BPC-157, TB-500, MOTS-c and any substance not approved for human use.

Tested athletes can fail a drug test from a “research” peptide even if it was sold legally.

Peptides in this article

  • Semaglutide: FDA-approved (Ozempic, Wegovy, Rybelsus) for diabetes, weight and heart risk
  • Tirzepatide: FDA-approved (Mounjaro, Zepbound) for diabetes, weight and sleep apnea
  • Sermorelin: Formerly FDA-approved (Geref); now available only as a compounded prescription
  • BPC-157: Research peptide: not approved for human use
  • TB-500: Research peptide: not approved for human use
  • Ipamorelin: Research peptide: not approved for human use

Frequently asked questions

Is it legal to buy research peptides?

Buying them for lab research is generally legal in the US. Selling them for people to inject is not, which is why sellers label them "not for human use."

What does FDA Category 2 mean?

It is an FDA list of bulk ingredients that compounding pharmacies may not use because of possible safety risks. Several popular peptides were added in 2023, and many moved off it in 2024 and 2026.

Can a doctor prescribe BPC-157?

A doctor can write a prescription, but a US pharmacy can legally compound BPC-157 only if it is allowed for compounding. In July 2026 an FDA advisory committee recommended allowing it, and the FDA hasn't decided.

Are peptides legal in sports?

Many are not. The World Anti-Doping Agency bans growth hormone peptides, BPC-157, TB-500 and any substance not approved for human use.

Sources

  1. FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
  2. Lexology (2024), FDA removes certain peptide bulk drug substances from Category 2
  3. NCPA (2026), FDA advisory committee nominates six peptides for pharmacies to compound
  4. Medscape (2026), FDA Proposes End to Mass GLP-1 Compounding
  5. World Anti-Doping Agency, The Prohibited List

Last updated .

More peptide articles